Antigen

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

Retrieved on: 
Wednesday, February 14, 2024

Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

Key Points: 
  • Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.
  • WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc.
  • The combined company’s common stock and warrants will begin trading on Nasdaq Global Market (“Nasdaq”) under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024.
  • The listing with Nasdaq is expected to provide Tevogen Bio increased access to capital to accelerate the development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Retrieved on: 
Tuesday, February 13, 2024

Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.

Key Points: 
  • Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.
  • The development of the C1 HCP ELISA Kit further demonstrates that Dyadic’s C1 protein expression platform is keeping pace with industry standards for HCP analysis in biopharmaceutical manufacturing.
  • Mark Emalfarb, CEO of Dyadic, commented, “I can’t stress enough the significance of our partnership with Cygnus, the C1 HCP assay provides adopters of our C1 microbial production platform a solution for testing C1 HCP impurity during product lot release testing, thereby enhancing the quality assurance process in biomanufacturing.
  • Our collaboration with Cygnus resulted in the development of a first-in-class C1 HCP ELISA assay, making a significant step toward greater adoption of the C1 technology globally.”
    Christine Dolan, Cygnus Technologies Chief Operating Officer, stated, “We are very excited about the launch of the highly anticipated C1 HCP ELISA Assay.

GeoVax Announces Multiple Patent Issuances and Allowances

Retrieved on: 
Tuesday, February 13, 2024

ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced multiple actions by global patent offices strengthening the Company’s intellectual property assets.

Key Points: 
  • The Japanese Patent Office issued a Decision of Grant notifying GeoVax of the allowance of the Company’s Patent Application No.
  • The U.S. Patent and Trademark Office issued Patent No.
  • 11,896,657 to GeoVax, pursuant to the Company’s patent application No.
  • David Dodd, GeoVax President and CEO, commented, “These patent actions add to our growing portfolio of wholly owned, co-owned, and in-licensed intellectual property, now standing at over 115 granted or pending patent applications spread over 24 patent families.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Retrieved on: 
Monday, February 12, 2024

HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

Key Points: 
  • HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
  • The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
  • These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
  • Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Retrieved on: 
Monday, February 12, 2024

HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

Key Points: 
  • HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
  • The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
  • These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
  • Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Advances Made in Grant to Improve Immunotherapy in Gastroesophageal Cancer

Retrieved on: 
Wednesday, February 7, 2024

They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.

Key Points: 
  • They are making strides in their objective of improving immunotherapy in gastroesophageal cancer by identifying and characterizing additional target antigens for next-generation cellular therapies.
  • One immunotherapy that has shown very positive results in blood cancers is Chimeric Antigen Receptor (CAR) T cell therapy.
  • "We are indeed proud to play a part in the development of the next-generation cellular therapy for gastroesophageal cancer by Drs.
  • Dana-Farber Cancer Institute provides expert cancer care while advancing the understanding of cancer and related diseases.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Retrieved on: 
Tuesday, February 6, 2024

ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced positive initial safety and immune response findings from its Phase 2 clinical trial at one month following administration of its Covid-19 vaccine, GEO-CM04S1. The trial, evaluating GEO-CM04S1 as a heterologous booster in 63 healthy adults who had previously received the Pfizer or Moderna mRNA vaccine (ClinicalTrials.gov Identifier: NCT04639466), was fully enrolled at the end of Sept 2023.

Key Points: 
  • The trial remains blinded to dose of vaccine received, with study subjects being followed for a total of one year.
  • To date, there have been no serious adverse events, and adverse events were in line with other routine vaccinations.
  • The immunological responses measured throughout the study period include both neutralizing antibodies against SARS-CoV-2 variants and specific T-cell responses.
  • We look forward to providing further updates regarding the successful progress of the clinical development of GEO-CM04S1.”

Global Research Antibodies Market Report 2024, Featuring Profiles of Abcam, Thermo Fisher Scientific, Cell Signaling Technology, Merck, Sino Biological & Bio-Rad - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024

The global market for research antibodies was valued at approximately $3.5 billion in 2022.

Key Points: 
  • The global market for research antibodies was valued at approximately $3.5 billion in 2022.
  • Among product segments, the primary antibody segment accounted for the highest market share in the global market for research antibodies in 2022.
  • The advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies.
  • This report segments the global market for research antibodies based on type of antibody, clonality, host, major reactivities, application, end user and region.